Hematology CME

The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 Credits^TM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

The BoardVitals Hematology and Oncology CME Review also features:

• Quick and Convenient CME
• Computer, phone, and tablet access
• Constantly updated up-to-date questions
• Questions that are targeted specifically to the exam
• Online CME tracker
• 100% Pass Guarantee
• Statistical comparison to other Hematology and Oncology test-takers (Nationally)

After completing this activity, you should be able to:

• Make a diagnosis
• Order and interpret results
• Assess risk, determine prognosis, and apply principles from epidemiologic studies
• Describe the underlying pathophysiology of disease and basic science knowledge

Target Audience: Hematologists and Oncologists

Maximize your CME allowance with MDCalc and get up to a $3,500 bonus gift card of your choice. Earn AMA PRA Category 1 Credits^TM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

Expert Advice and Insightful Commentary

The MKSAP® 19 Audio Companion sheds light on the latest diagnostic approaches, management strategies, and treatment guidelines. In this comprehensive audio CME program, you’ll join host Donald L. Deye, MD, FACP, as he leads lively discussions with esteemed colleagues in 11 internal medicine subspecialties. Listen as experienced clinicians from some of the world’s finest medical institutions share patient stories, insightful views of recent clinical advances, and more.

Anytime, Anywhere Audio CME

With the MKSAP 19 Audio Companion, you get:

• All-new advice and commentary — a reliable, and entertaining way to learn current oncology trends, the latest approaches to diabetes treatment, COVID updates, new tactics for managing patients with COPD, and so much more
• An easy way to prep for your ABIM certification or MOC exam
• Flexible learning to fit your schedule — in your car, between appointments, while you work out
• Companion booklets — high-impact PDF learning aids to quickly review and retain key points (print booklets available for an additional charge)
• The opportunity to earn AMA PRA Category 1 Credits™ and ABIM MOC points
• Four FREE sets of extension questions — a $350 value that brings you incremental AMA PRA Category 1 Credits™ and MOC points

Audience

General internists and primary care physicians; subspecialists who need to remain up to date in internal medicine; residents preparing for the certifying examination in internal medicine; physicians preparing for the recertification examination. 

Learning Objectives

• Discuss the most clinically relevant patient care information in all subspecialties of Internal Medicine based on the medical literature of the last 3 to 5 years
• Describe clinical situations in which this new knowledge will improve the quality of care
• Diagnose disease states that are less common and sometimes overlooked and confusing
• Determine when to refer patients for surgery or care by subspecialists

Learn Now: Thrombosis CME from the Experts

This online CME course from the North American Thrombosis Forum provides a comprehensive review of the most significant changes and advances impacting the care of patients who have — or are at risk for — thrombotic disorders. World-renowned experts and leading clinical faculty share key updates on the prevention, diagnosis, and treatment of thrombosis and related conditions.

Thrombosis and Thromboembolism is continuing medical education that will help you to:

• Identify the etiology and pathophysiology of atherothrombosis
• Recognize the link between inflammation and thrombotic illnesses
• Explain new tools for stroke prevention and prediction in atrial fibrillation
• Identify the optimal duration of anticoagulation for PE and DVT
• Provide advanced therapies such as thrombolysis, catheter-directed therapy, and surgical embolectomy
• Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
• Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
• Manage a high-risk pregnancy
• And more…

Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

Pricing Options

• 6 Month subscription: All 6,339 CME Activities – $249 per 6 months
• Annual subscription: All 6,339 CME Activities – $349 per 1 year
• Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever – $1999

Essential Hematology and Oncology CMEThe Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology is a case-based online video CME program focused on improving overall knowledge and clinical competency with comprehensive updates on basic principles, changing guidelines, and therapeutic strategies. Continuing medical education areas for practice improvement include:

• Hematopoiesis and Cytokines
• Platelet Disorders
• Molecular Basis of Cancer
• New Therapies (Pharmacology)
• Palliative Care (Management of Symptoms/End of Life)
• Gastrointestinal Cancers (Neuroendocrine/Esophageal/Pancreas/Colorectal)
• Thoracic Oncology (Head/Neck/Lung/Thyroid)
• and many more…

Activity Description / Statement of Need:

In this online, self-learning activity:

Thalassemias belong to a group of recessively inherited blood disorders characterized by little or no hemoglobin production and chronic anemia of varying severity. Alpha-thalassemia (AT) is most commonly found in people of Mediterranean, Middle Eastern, Asian, and North African descent. Worldwide, 5% of people are AT carriers, with a much higher prevalence in certain regions (eg, up to 23% in Southeast Asia). AT is typically caused by deletions of one or more α-globin genes, of which there are 4 in total, leading to reduced or abolished α-globin production; nondeletional forms of AT can also occur and are generally more severe. The loss of functional α-globin disrupts the globin chain equilibrium, leading to excess γ- and β-globin chain formation and causing ineffective erythropoiesis.

Target Audience:

The following healthcare professionals: hematologists; physician assistants, nurse practitioners, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who may clinically encounter patients with AT.

Includes eleven online, self-learning activities:

• The state of prostate cancer treatment: advances in approach for advanced disease –  (1 hr CE) ACCME ACPE MOC
• Ongoing challenges and optimal approaches in the management of metastatic colorectal cancer (mCRC) – (1 hr CE) ACCME ACPE MOC
• Advanced systemic mastocytosis: from recognition to treatment (Tsewang Tashi MD) – (1 hr CE) ACCME ACPE MOC
• Pancreatic Cancer: Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – (0.75 hr CE) ACCME ACPE MOC
• Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Waddah Arafat MD) – (0.75 hr CE) ACCME ACPE MOC
• Taking the next step in the management of relapsed or refractory follicular lymphoma (Eric Tam MD) – (1 hr CE) ACCME ACPE MOC
• Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC) – (1 hr CE) ACCME ACPE MOC
• Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape – (1 hr CE) ACCME ACPE MOC
• Contemporary treatment approaches in the management of chronic graft-versus-host disease (GVHD) – (1 hr CE) ACCME ACPE MOC
• Hitting management strategies of metastatic nasopharyngeal carcinoma on the nose – (1 hr CE) ACCME ACPE MOC
• Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 – (0.75 hr CE) ACCME ACPE MOC

Target Audience: HCPs including: medical oncologists, oncology surgeons, and pathologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology, hematology, gastroenterology, urology, with some overlap in otolaryngology, transplant medicine, allergy/immunology, nephrology, and hepatology

Activity Description / Statement of Need:
In this online, self-learning activity:

Transthyretin-mediated amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. The role of the TTR protein is to transport thyroxine and retinol-binding proteins, and it is vital for cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations, which may account for wild-type ATTR (wtATTR), while a hereditary form of ATTR (hATTR) may be passed to offspring through autosomal dominant inheritance. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.

Target Audience:
The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.

Activity Description / Statement of Need:
In this online, self-learning activity:

Acute hepatic porphyria (AHP) is an umbrella term for four types of acute porphyria, the most severe of which is acute intermittent porphyria (AIP). An estimated 80% of AHP cases are AIP, which is an inherited autosomal dominant condition that results from mutations of the third enzyme of heme synthesis, porphobilinogen deaminase. In the Western countries, it is estimated that approximately 1 in 2000 individuals are carriers of the relevant mutated genotype, although the majority have latent AIP and are clinically asymptomatic. Acute attacks occur in less than 10% of the at-risk population, reflecting the role of environmental factors, such as alcohol use, infections, and hormonal changes, among others. AHP symptoms are believed to be caused by ALAS1-mediated accumulation of ALA and PBG in the liver and bloodstream, leading to neurotoxicity.

Target Audience:
The following HCPs: hematologists and gastroenterologists; physician assistants, nurse practitioners, and pharmacists who practice in any of the aforementioned areas of specialties; and any other healthcare professionals with an interest in or who clinically encounter patients with AHP.

Activity Description / Statement of Need:
In this online, self-learning activity:

Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

Target Audience:
HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.

Sickle cell disease (SCD) is the most common monogenic blood disorder, affecting millions of people worldwide and approximately 100,000 Americans. Although it may be found in various areas of the world, SCD predominantly affects individuals of African or Hispanic heritage. It is caused by the inheritance of b-globin alleles that code for hemoglobin S, resulting in an amino acid substitution in hemoglobin’s b chain and clinical disease. Patients with SCD have impaired circulation, and lysis of the erythrocytes contributes to a chronic inflammatory response, causing severe pain and less efficient oxygen delivery. The hallmark clinical features of SCD are hemolytic anemia and painful vaso-occlusive crises (VOCs), which may lead to emergency department visits, hospitalization, and potentially fatal complications such as acute chest syndrome, stroke, or pneumonia. In one US study, 45% of deaths among people with SCD were related to cardiopulmonary causes, and VOCs alone have been shown to increase the risk of death by 50%. SCD may disrupt employment or school and is associated with a significant reduction in quality of life. This learning activity has been designed to bring HCPs’ knowledge of rationale behind treatment of SCD up to date and to enhance their competence and performance in the condition’s management.

Activity Description:

In this online, self-learning activity:

Pyruvate kinase (PK) is an enzyme that plays a major role in a metabolic pathway integral to the production of ATP, and a deficiency in the enzyme (PKD) is one of the most common enzyme-related glycolytic defects in a pathway integral to the production of ATP. It is transmitted as an autosomal recessive trait and is caused by mutations in the PKLR gene on chromosome 1, and over one hundred eighty of these mutations have been associated with PKD. While PKD affects approximately five people of European descent per 100,000 (data in other patient populations are lacking), it is one of the more frequent causes of chronic hemolysis. Anemia arising from the condition may range from mild and fully compensated to life-threatening in severity.

Target Audience:

HCPs including: hematology; nurse practitioners, physician assistants, and pharmacists who specialize in hematology; and those with an interest in or may clinically encounter patients with PKD.